Background Minimal change disease (MCD) is characterized by increased urinary excretion of CD80, whereas focal segmental glomerulosclerosis (FSGS) is associated with increased serum soluble urokinase-type plasminogen activator receptor (suPAR). The aim of the study was to assess whether the simultaneous measurement of urinary CD80 and serum suPAR helps differentiate MCD and FSGS. Methods Urine and sera were collected from patients with MCD in relapse or in remission, from FSGS patients with nephrotic syndrome, and from healthy individuals. CD80 and suPAR were measured by ELISA. Results Urinary CD80 was significantly increased in MCD patients in relapse compared with those in remission and with FSGS patients and control individuals. Serum suPAR levels were significantly higher in patients with FSGS when compared with MCD patients in relapse. Urinary suPAR showed a positive correlation with proteinuria in MCD in relapse and FSGS patients, whereas urinary CD80 correlated with proteinuria only in MCD patients in relapse. Conclusion Urinary CD80 is elevated in MCD patients in relapse compared with FSGS patients. In contrast, serum suPAR is significantly elevated in FSGS patients. The consistent pattern of these two biomarkers in MCD and FSGS suggests that these two conditions represent different entities rather than a continuum spectrum of one disease.
Introduction
Idiopathic nephrotic syndrome (INS) is defined as the association of nephrotic syndrome with nonspecific glomerular abnormalities, including minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and mesangial proliferative glomerulonephritis [1] . MCD and FSGS are thought to be podocytopathies that can share a similar renal pathology, especially in early stages [2] . Proteinuria in these conditions arises from intrinsic or extrinsic primary podocyte injury and is represented by foot process effacement. In MCD, podocytes exhibit diffuse foot process effacement, and the cell number is preserved. In FSGS, the number of podocytes is decreased as a consequence of sublethal injury or from apoptotic or necrotic death. Podocytes detach from the glomerular basement membrane (GBM), leaving denuded GBM areas. This naked GBM contacts the parietal epithelium, forming a synechia [3] , leading to focal glomerulosclerosis. Although these glomerulopathies are clearly defined histopathologically, in some cases, because of biopsy sampling, initial findings may be consistent with MCD but repeat renal biopsy shows features typical of FSGS [4] . These factors raise the issue that MCD and FSGS can be easily misdiagnosed or may in some instances represent a continuum spectrum of the same disease. Podocyte dysfunction in MCD and FSGS is probably the result of response of local or systemic mediators (vascular permeability factor) [5] [6] [7] [8] and in some cases of FSGS, in slit diaphragm protein mutations [9] . In MCD, the circulating factor has not yet been identified. Local mediators may include podocyte-derived angiopoietin-like-4 (Angptl4) [8] and CD80 [10, 11] . We have shown that there is increased podocyte CD80 expression with a concomitant increased in urinary CD80 excretion in MCD [10, 11] . No such increase was found in FSGS patients [11] .
Recently, soluble urokinase-type plasminogen activator receptor (suPAR) has been reported to be elevated in the serum of individuals with primary FSGS [12] and may represent a circulating factor driving proteinuria in this condition. In experimental mouse models [12] , circulating suPAR deposits in the glomeruli and binds to and activates podocyte αvβ3 integrin, causing foot process detachment from the GBM and resulting in proteinuria. Removal of suPAR using plasmapheresis in patients with recurrent FSGS to a level below the threshold required to activate αvβ3 integrin on human podocytes was associated with remission [12] . The aim of the study reported here was to begin to assess the diagnostic potential of simultaneous measurement of urinary CD80 and serum and urinary suPAR to differentiate between patients with MCD and FSGS.
Methods
Patients Twenty-six children and adolescents with biopsyproven MCD (aged 2-21 years, 11 female and 15 male patients) were enrolled (Table 1) . Five patients were studied only during relapse and six only during remission; 15 were studied in both relapse and remission. Three patients participated in the relapse group, although their serum albumin was slightly >3.5 g/dl. They were considered to be in early relapse according to their urinary protein/creatinine ratio. On followup a week later, they presented with edema and low serum albumin. Six patients were enrolled in the remission group, despite serum albumin being <3.5 g/dl, based on their low protein/creatinine ratio. All MCD patients were followed at the University of Florida.
Two cohorts of patients with biopsy-proven FSGS were included in this study (Table 2) . No patient presented secondary-type FSGS. One cohort enrolled 15 patients aged 19-64 years who were followed at the Hospital Vall d'HebronBarcelona, Spain. The second group comprised 11 patients aged 7-19 years seen at the University of Florida. All FSGS patients had active nephrotic syndrome at the time of sample collection.
Sixteen individuals aged 4-17 years served as controls (Table 3 ). These individuals were followed at the University of Florida-Pediatric Nephrology Outpatient Clinic (five hypertension, four hematuria, four urinary tract infection, and one each of lithiasis, primary lymphedema, and asymptomatic elevated renin activity). None of these control individuals had any underlying immunological disorder.
The study was approved by the Institutional Review Boards of both Institutions, and informed consent, and assent when indicated, was obtained from participants.
Definitions MCD was defined according to the established criteria by the International Study for Kidney Diseases in Children [13] . Patients with FSGS had renal biopsies demonstrating focal and segmental consolidation of the glomerular tuft with and without synechia and hyalinosis, with either negative immunofluorescence or only segmental immunoglobulin M (IgM) or minimal C3 staining and no electrondense deposits on electron microscopy. The different subtypes of FSGS were classified according to D'Agati et al. [14] . Relapse was defined as the presence of proteinuria (urinary protein/creatinine ratio > 3.0 mg/mg or ≥3 + using the tetrabromophenol-citrate buffer colorimetric qualitative dipstick test), hypoalbuminemia (< 3.5 g/dl), and edema. Remission was defined as no proteinuria using the colorimetric qualitative test or by urinary protein/creatinine ratio < 0.2 mg/mg (or <0.5 for children under the age of 5 years).
Urinary CD80 measurements CD80 was measured using a commercially available enzyme-linked immunosorbent assay (ELISA) kit (Bender MedSystems, Burlingame, CA, USA); results were adjusted for urinary creatinine excretion.
suPAR measurements Serum and urinary suPAR was measured with the Quantikine Human suPAR Immunoassay (R&D Systems) [9] .
Urinary protein and creatinine and serum albumin were measured using an autoanalyzer.
Statistical analyses Data graphics and statistical analysis were performed using Prism 5 (GraphPad). Kruskal-Wallis and Mann-Whitney tests were applied to evaluate differences between groups; Spearman correlation coefficient was used to calculate urinary CD80 and proteinuria and urinary suPAR and proteinuria. P <0.05 was regarded as statistically significant. Values are presented as means ± standard deviation (SD), unless otherwise stated.
Results
Demographics and laboratory tests at the time of sample collection are shown on Tables 1-3 .
Urinary CD80 excretion in MCD and FSGS (Fig 1a) Urinary CD80 excretion was significantly increased in MCD patients in relapse (448±564 ng/g creatinine) when compared with patients with MCD in remission (35.2±58 ng/g No differences were observed in CD80 urinary excretion between MCD patients in remission and those with FSGS. Urinary CD80 levels were significantly higher in MCD patients in remission and in FSGS patients when compared with controls. Nine of 13 available controls had a urinary CD80 <0.5 ng/g creatinine (Fig. 1a) .
Serum suPAR (Table 4 ) Serum suPAR levels were significantly higher in patients with FSGS compared with MCD patients in relapse (p =0.02) (Fig. 1b) , though there was considerable overlap. Serum suPAR levels did not show significant difference among FSGS individual histological FSGS subtypes.
Urinary suPAR excretion in MCD and FSGS (Fig. 2 ) Urinary suPAR levels were increased in MCD patients in relapse and those with FSGS when compared with MCD patients in remission (p <0.001). MCD patients in relapse showed greater concentration of urinary suPAR than control individuals (p =0.007). There was no significant difference in urinary suPAR levels between MCD patients in relapse and those with FSGS. No statistically significance differences were observed between FSGS patients and control individuals. A significant correlation was observed between urinary CD80 and urinary suPAR Proteinuria, urinary CD80, and urinary suPAR Urinary CD80 showed a strong positive correlation with the degree of proteinuria in MCD patients (r =0.75, p <0.001) (Fig. 3a) , whereas no such correlation was found in FSGS patients (r =0.31, p =0.16) (Fig. 3b) . Urinary suPAR had a positive correlation with proteinuria in both MCD (r =0.69, p <0.001) (Fig. 3c) and FSGS (r =0.47, p =0.02) patients (Fig. 3d) .
Discussion
This study suggests that MCD and FSGS have different pathogenetic mechanisms relative to the development of proteinuria. CD80 appears to play a major role in MCD, whereas suPAR is implicated in FSGS. These data indicate that MCD and FSGS represent two different entities rather than a continuum spectrum of one disease. The role of CD80 in proteinuria has been studied in experimental models of proteinuria [15] . Reiser et al. found that mice injected with lipopolysaccharide (LPS) developed proteinuria with glomerular podocyte CD80 expression likely through podocyte Toll-like receptor 4 expression. Our group previously reported data supporting the role of CD80 in MCD [10, 11] . Indeed, patients with MCD in relapse showed increased urinary CD80 compared with patients with MCD in remission, control individuals, or individuals with other glomerular diseases, including FSGS. uPAR and suPAR play a critical role in human FSGS and animal models of proteinuria resembling FSGS [12, 16] . uPAR is a glycosylphosphatidylinositol (GPI)-anchored threedomain protein that not only serves as receptor for urokinase but also interacts with other transmembrane protein, such as integrins. Mice administered LPS developed foot process effacement and proteinuria. In contrast, when LPS was administered to uPAR knockout mice (Plaur−/−), there was no development proteinuria. Exogenous suPAR administration to uPAR knockout mice (Plaur−/−) led to albuminuria and suPAR deposition along the podocytes, as well as activation of αvβ3 integrin [12] .
A recent study showed that 84.3 % and 55.3 % of FSGS patients with normal estimated glomerular filtration rate (eGFR) from two different populations had elevated serum suPAR [17] . In addition, Wei et al. studied the level of serum suPAR in patients with different glomerulopathies (including 63 patients with FSGS) and in a normal population and found that most patients with a serum suPAR >3,000 pg/ml had FSGS as the underlying disease. However, in some FSGS patients, serum suPAR levels were no different from normal controls or patients with MCD. It is not clear whether the low suPAR levels in these FSGS patients is due to genetic mutations, where the defect is at the SD standard deviation, NOS not otherwise specified level of other podocyte genes and not associated with a circulating factor, or to suPAR with different biochemical properties that are not readily detected by commercial ELISA tests. It is also possible that pathologically processed suPAR is podocyte pathogenic, even though the total measured suPAR levels are low or normal in these FSGS patients. This study suggests that serum suPAR and urinary CD80 are potential biomarkers that can be used in concert and that might allow differentiation between FSGS and MCD. Such a biomarker-driven additional characterization helps in the correct diagnosis of the proteinuric disorder. A pattern of elevated serum suPAR and normal urinary CD80 is consistent with the diagnosis of FSGS. In contrast, a normal or mildly elevated serum suPAR with an elevated urinary CD80 rather suggests MCD as the underlying pathology (Fig. 4) [11] . Of interest is a patient with FSGS secondary to podocin mutation in whom we found a distinctive mixed pattern consistent with elevated serum suPAR and urinary CD80. Therefore, the combination of these two biomarkers may help differentiate between primary and genetic forms of FSGS [18] . Clearly, more work is needed to describe the latter type of patient in greater detail.
Urinary suPAR is elevated in both FSGS and in MCD patients in relapse when compared with controls. This finding supports the notion that suPAR is excreted in larger amounts if the filtration barrier is leaky and that in MCD patients, it might rather be the consequence than the cause of proteinuria. In fact, this study shows a significant correlation between urinary suPAR and proteinuria in both FSGS patients and MCD patients in relapse. These findings may have clinical and pathogenic implications. A renal biopsy to define the underlying pathology would be indicated if the suPAR-CD80 pattern suggests FSGS in order to appropriately guide therapy and deliver a prognosis. Testing for suPAR might currently be best justified in FSGS pretransplant evaluation wherein high levels might call for preemptive plasmapheresis, a treatment known to lower suPAR levels and reduce the number of posttransplant FSGS recurrences. suPAR testing that includes podocyte integrin activation assays [11] might also be of value in managing posttransplant FSGS recurrence to assess the continued need for plasmapheresis [12] .
This study further suggests that proteinuria in MCD and FSGS have different pathogenic mechanisms. We postulated that increased podocyte CD80 expression in MCD is a result of a circulating factor that stimulates TLR3 or TLR4 [19] . We demonstrated in cell-culture studies that TL3 stimulation is followed by translocation of the p65 subunit from the cytoplasm to the nucleus, resulting in activation of nuclear factor kappa-B (NFκB) and subsequent CD80 upregulation. CD80 upregulation is followed by changes in the actin cellular cytoskeleton, resulting in opening of the slit diaphragm and subsequent proteinuria.
The mechanism by which increased serum suPAR levels results in proteinuria in FSGS is not likely due to podocyte CD80 stimulation. Urinary suPAR did not show a correlation with urinary CD80 in FSGS patients. In addition, urinary suPAR was elevated in FSGS and in MCD patients in relapse, but no statistical differences were found among the groups tested despite the fact that FSGS patients had a greater serum suPAR concentration than MCD patients, suggesting production of suPAR in FSGS. Finally, we observed no CD80 podocyte expression in FSGS patients.
In summary, urinary CD80 is elevated in MCD patients in relapse compared with FSGS patients who, in contrast, have elevated concentration of serum suPAR. The consistent pattern of these two biomarkers in MCD and FSGS suggests that they represent different entities rather than a continuum of one disease. Moreover, the combination of these biomarkers may help when differentiating between genetic and primary FSGS. Our findings, therefore, could have important clinical significance regarding diagnosis of these diseases.
